

Fax Referral To: 1-888-280-1191 OR 787-759-4161

Phone: 1-888-280-1190 OR 787-759-4162

Email	Referral	To:	Customer.ServiceFax@CVSHealth.com	

Address: 280 Avenida Jesus T. Pinero Ste B Rio Piedras, PR 00927 Six Simple Steps to Submitting a Referral

PATIENT INFO	RMATION (Corr	nplete or include demographic sheet)	
Patient Name:			DOB:
			e, ZIP Code:
Gender: 🗌 Male 🗌			
Preferred Contact M	lethods: 🗌 Phone ((to primary # provided below) 🗌 Text (to cell	# provided below) Email (to email provided below)
		e to contact via text or email, Specialty Pharm	
Primary Phone:		Alternate	e Phone:
		lame (Last, First):	
Relationship to min	or:	· · ·	
Email:		Last Four of SSN:	Primary Language:
2 PRESCRIBER	INFORMATIC	ON	
Prescriber's Name: _		State Li	cense #:
NPI #:	_ DEA #:	Group or Hospital:	
Address:		City, State, ZIP	Code:
Phone:			Contact's Phone:

3 INSURANCE INFORMATION Please fax copy of prescription and insurance cards with this form, if available (front and back)

4 DIAGNOSIS AND CLINICAL INFORMATION

Needs by Date:	_ Ship to: 🗌 Patient 🗌 Office 🗌 Other:
<u> Diagnosis (ICD-10):</u>	
M06.9 Rheumatoid Arthritis, U	nspecified
M32.1 Systemic lupus erythem	atosus (SLE)
M32.14 Glomerular disease in	systemic lupus erythematosus
M45.9 Ankylosing Spondylitis	of Unspecified Sites in Spine
L40.50 Arthropathic Psoriasis,	Unspecified
L40.59 Other Psoriatic Arthrop	athy
M08.00 Unspecified Juvenile	Rheumatoid Arthritis of Unspecified Site
K50.00 Crohn's Disease of Sm	all Intestine Without Complications
K50.10 Crohn's Disease of Lar	ge Intestine Without Complications
K50.80 Crohn's Disease of Sm	all & Large Intestine Without Complications
🗌 K50.90 Crohn's Disease, Unsp	ecified, Without Complications
K51.00 Ulcerative (chronic) pa	acolitis without complications
K51.30 Ulcerative (chronic) red	tosigmoiditis without complications
K51.50 Left sided colitis withou	t complications
K51.90 Ulcerative colitis, unsp	cified, without complications
Other Code:	Description:

Patient Clinical Information:

Allergies:	Weight:	lb/kg Height:in/cm	۱
TB test Result	Date of test: _//		
Positive ANA or anti-dsDNA test? Yes	No Date of test: _//		
Hepatitis status:			
New to therapy? Yes No If n	o, next dose due:		

Medications A-D

(Actemra,	Avsola,	Benly	ysta)

		Please Complete Patient and Prescriber Information	
Patient Name:			
Prescriber Name:Prescriber Phone:Prescriber Phone:			
Patient Clinic	al Information:		
Allergies:		Weight:lb/kg Height: ative Date of test: _//	In/cm
	TION INFORMATIC	N	
MEDICATI ON	STRENGTH	DOSE & DIRECTIONS	QUANTITY/REFILLS
Actemra	☐ 80 mg/4 mL ☐ 200 mg/10 mL ☐ 400 mg/20 mL	Induction Dose: Infuse 4 mg/kg every 4 weeks Maintenance Dose: Infuse 8 mg/kg every 4 weeks Other:	Quantity: Refills:
Actemra	162 mg/0.9 mL prefilled syringe	 For patients weighing <100 kg: Inject 162 mg SC every other week, followed by an increase to every week based on clinical response For patients weighing ≥ 100 kg: Inject 162 mg SC every week. 	Quantity: Refills:
Avsola	100 mg vial	Ankylosing Spondylitis Induction Dose: Infuse IV at 5 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 6 weeks thereafter Ankylosing Spondylitis Maintenance Dose: Infuse IV at 5 mg/kg (Dose =mg) every 6 weeks Crohn's Disease (Adult and Pediatric ≥6 years old) Induction Dose: Infuse IV at 5 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 8 weeks thereafter Crohn's Disease (Adult) Maintenance Dose: Infuse IV at 5-10 mg/kg (Dose =mg) every 8 weeks Crohn's Disease (Pediatric ≥6 years old) Maintenance Dose: Infuse IV at 5 mg/kg (Dose =mg) every 8 weeks Plaque Psoriasis & Psoriatic Arthritis Induction Dose: Infuse IV at 5 mg/kg (Dose =mg) every 8 weeks thereafter Plaque Psoriasis & Psoriatic Arthritis Maintenance Dose: Infuse IV at 5 mg/kg (Dose =mg) every 8 weeks thereafter Plaque Psoriasis & Psoriatic Arthritis Maintenance Dose: Infuse IV at 5 mg/kg (Dose =mg) every 8 weeks Rheumatoid Arthritis Induction Dose: Infuse IV at 5 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 8 weeks thereafter Plaque Psoriasis & Psoriatic Arthritis Maintenance Dose: Infuse IV at 5 mg/kg (Dose =mg) every 8 weeks Cheumatoid Arthritis Induction Dose: Infuse IV at 3 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 8 weeks thereafter Meumatoid Arthritis Maintenance Dose: Infuse IV at 3-10 mg/kg (Dose =mg) every 4, 6 or 8 weeks (circle one) Ulcerative Colitis (Adult and Pediatric ≥6 years old) Induction Dose: Infuse IV at 5 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 8 weeks thereafter Meumatoid Arthritis Maintenance Dose: Infuse IV at 5 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 8 weeks thereafter I Ulcerative Colitis (Adult and Pediatric ≥6 years old) Induction Dose: Infuse IV at 5 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 8 weeks thereafter I Ulcerative Colitis (Adult and Pediatric ≥6 years old) Maintena	Quantity: # of 100 mg vial(s) Refills:
Benlysta	☐ 120 mg 5 mL vial ☐ 400 mg 20 mL vial	Induction Dose: 10 mg/kg IV (Dose =mg) at 2-week intervals for the first 3 doses and at 4-week intervals thereafter. Infuse IV over 1 hour.	Quantity: vials Refills:
Patient is interest	ed in patient support programs	STAMP SIGNATURE NOT ALLOWED Ancillary supplies and kits provided	as needed for administration

6PRESCRIBER SIGNATURE REQUIRED (STAMP SIGNATURE NOT ALLOWED)

"Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Substitution /		May Substitute / Product Selection Permitted /	
DAW / May Not Substitute		Substitution Permissible	
Prescriber's Signature:Date:		Prescriber's Signature: Date:	
CA, MA, NC & PR: Interchange is mandated unless Prescriber v	vrites the words " No Substitution "	I ATTN: New York and Iowa provider	rs, please submit electronic prescription

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

 $@2022\ \text{CVS}$ Specialty and one of its affiliates. 75-55131A $\$ 05/18/22 $\$

Autoimmune IV Enrollment Form Medications E-O

		-	
(Entvvio, Inflectra,	Infliximab.	Orencia)	

		(Lintyvio, innectra, innuximab, Orencia)	
		Please Complete Patient and Prescriber Information	
		Patient DOB:	
		Prescriber Phone:	
Patient Clinical I		Martineau III (Inc. 11) (alta)	h. (
		Weight:lb/kg Height:lb/kg Height:	In/cm
	Positive Neg		
MEDICATION	STRENGTH		QUANTITY/REFILLS
	300 mg in a	Induction Dose: 300 mg infused IV over 30 minutes at 0, 2 and 6 weeks, then	Quantity:
🗌 Entyvio	single dose vial in individual	every 8 weeks thereafter <u>Maintenance Dose</u> : 300 mg infused IV over 30 minutes every 8 weeks	Quantity: Refills:
	carton	Other:	Neniiis
☐ Inflectra ☐ Infliximab	100 mg vial	 Ankylosing Spondylitis Induction Dose: Infuse IV at 5 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 6 weeks thereafter Ankylosing Spondylitis Maintenance Dose: Infuse IV at 5 mg/kg (Dose =mg) every 6 weeks Crohn's Disease (Adult and Pediatric ≥6 years old) Induction Dose: Infuse IV at 5 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 8 weeks thereafter Crohn's Disease (Adult) Maintenance Dose: Infuse IV at 5-10 mg/kg (Dose =mg) every 8 weeks Crohn's Disease (Pediatric ≥6 years old) Maintenance Dose: Infuse IV at 5 mg/kg (Dose =mg) every 8 weeks Plaque Psoriasis & Psoriatic Arthritis Induction Dose: Infuse IV at 5 mg/kg (Dose =mg) every 8 weeks thereafter Plaque Psoriasis & Psoriatic Arthritis Maintenance Dose: Infuse IV at 5 mg/kg (Dose =mg) every 8 weeks thereafter Plaque Psoriasis & Psoriatic Arthritis Induction Dose: Infuse IV at 5 mg/kg (Dose =mg) every 8 weeks thereafter Plaque Psoriasis & Psoriatic Arthritis Maintenance Dose: Infuse IV at 5 mg/kg (Dose =mg) every 8 weeks thereafter Plaque Psoriasis & Psoriatic Arthritis Maintenance Dose: Infuse IV at 5 mg/kg (Dose =mg) every 8 weeks Rheumatoid Arthritis Induction Dose: Infuse IV at 5 mg/kg (Dose =mg) every 8 weeks Rheumatoid Arthritis Induction Dose: Infuse IV at 3 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 8 weeks thereafter Rheumatoid Arthritis Maintenance Dose: Infuse IV at 3 mg/kg 	Quantity: # of 100 mg vial(s) Refills:
Orencia	250 mg vial	(Dose =mg) every 4, 6 or 8 weeks (circle one) □ Ulcerative Colitis (Adult and Pediatric ≥6 years old) Induction Dose: Infuse IV at 5 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 8 weeks thereafter □ Ulcerative Colitis (Adult and Pediatric ≥6 years old) Maintenance Dose: Infuse IV at 5 mg/kg (Dose =mg) every 8 weeks □ Other:	Quantity: Refills:
	, padent support programs	Anomaly supplies and kits provide	a as needed for administration

6PRESCRIBER SIGNATURE REQUIRED (STAMP SIGNATURE NOT ALLOWED)

"Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Substitution /		May Substitute / Product Selection Permitted /	
DAW / May Not Substitute		Substitution Permissible	
Prescriber's Signature:Date:		Prescriber's Signature:Date:	
CA, MA, NC & PR: Interchange is mandated unless Prescriber w	rites the words "No Substitution"	ATTN: New York and Iowa providers	, please submit electronic prescription

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

©2022 CVS Specialty and one of its affiliates. 75-55131A 05/18/22

Medications R-Z

	•	micade, Renflexis, Rituxan, Saphnelo, Simponi ARIA, Stelara)	
Detient Newser		Please Complete Patient and Prescriber Information	
		Patient DOB:	
		Prescriber Phone:	
Patient Clinical		Weight: Ib/kg Height:	In /om
TB tost Posult		_Weight:lb/kg Height: tive Date of test: _//	
MEDICATION	STRENGTH	DOSE & DIRECTIONS	QUANTITY/REFILLS
MEDICATION	STRENGTH		QUANTIT T/REFILLS
☐ Remicade	100 mg vial	 Ankylosing Spondylitis Induction Dose: Infuse IV at 5 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 6 weeks thereafter Ankylosing Spondylitis Maintenance Dose: Infuse IV at 5 mg/kg (Dose =mg) every 6 weeks Crohn's Disease (Adult and Pediatric ≥6 years old) Induction Dose: Infuse IV at 5 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 8 weeks thereafter Crohn's Disease (Adult) Maintenance Dose: Infuse IV at 5-10 mg/kg (Dose =mg) every 8 weeks Crohn's Disease (Pediatric ≥6 years old) Maintenance Dose: Infuse IV at 5 mg/kg (Dose =mg) every 8 weeks Crohn's Disease (Pediatric ≥6 years old) Maintenance Dose: Infuse IV at 5 mg/kg (Dose =mg) every 8 weeks Plaque Psoriasis & Psoriatic Arthritis Induction Dose: Infuse IV at 5 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 8 weeks thereafter Plaque Psoriasis & Psoriatic Arthritis Maintenance Dose: Infuse IV at 5 mg/kg (Dose =mg) every 8 weeks Rheumatoid Arthritis Induction Dose: Infuse IV at 3 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 8 weeks thereafter Rheumatoid Arthritis Maintenance Dose: Infuse IV at 3-10 mg/kg (Dose =mg) every 4, 6 or 8 weeks (circle one) Ulcerative Colitis (Adult and Pediatric ≥6 years old) Induction Dose: Infuse IV at 5 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 8 weeks thereafter Ulcerative Colitis (Adult and Pediatric ≥6 years old) Induction Dose: Infuse IV at 5 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 8 weeks thereafter Ulcerative Colitis (Adult and Pediatric ≥6 years old) Induction Dose: Infuse IV at 5 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 8 weeks thereafter Ulcerative Colitis (Adult and Pediatric ≥6 years old) Maintenance Dose: Infuse IV at 5 mg/kg (Dose =mg) at weeks 0, 2, 6 and every 8 weeks thereafter Ulcerative Colitis (Adult and Pediatric ≥6 y	Quantity: # of 100 mg vial(s) Refills:
Rituxan	☐ 100 mg/10 mL vial ☐ 500 mg/50 mL vial	Infuse two doses of 1000 mg separated by 2 weeks Other:	Quantity: vials Refills:
Saphnelo	300 mg/2 mL (150 mg/mL)	300 mg IV over a 30-minute period, every 4 weeks Other:	Quantity: vials Refills:
☐ Simponi ARIA	50 mg/4 mL in a single use vial	Initial Dose: Inject SC 200 mg initially (given as 2 subcutaneous injections of 100 mg each) at week 0, followed by 100 mg at week 2 and then 100 mg every 4 weeks Maintenance Dose: Inject SC 100 mg every 4 weeks Other:	Quantity: Refills:
Stelara	130 mg/26 mL (5 mg/mL) IV single-dose vial	Single IV Induction Dose: 55 kg or less 260 mg at week 0: # of vials to be used 2 more than 55 kg to 85 kg 390 mg at week 0: # of vials to be used 3 more than 85 kg 520 mg at week 0: # of vials to be used 4 Other:	Quantity: 2 Vials 3 Vials 4 Vials Refills: 0

BPRESCRIBER SIGNATURE REQUIRED (STAMP SIGNATURE NOT ALLOWED)

"Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Substitution / DAW / May Not Substitute Prescriber's Signature:Date:		May Substitute / Product Selection Permitted / Substitution Permissible Prescriber's Signature:	Date:
CA MA NC & PR: Interchange is mandated unless Prescriber writes the words "No Substitution"		ATTN: New York and Iowa provide	rs please submit electronic prescription

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature. ©2022 CVS Specialty and one of its affiliates. 75-55131A 05/18/22 Page 4 of 5

Nursing Medications

	Please C	omplete Patient and Prescriber Information		
Patient Name: Patient DOB:				
Prescriber Name:				
Patient Clinical Information				
Allergies:	Weight:	lb/kg Height: Date of test://	In/cm	
		Date of test: _//		
5 PRESCRIPTION INFORI	MATION			
Complete Items below, req	uired for Home In	ifusion:		
MEDICATION/SUPPLIES	ROUTE	DOSE/STRENGTH/DIRECTIONS	QUANTITY/REFILLS	
Catheter PIV PORT PICC	IV	Catheter Care/Flush – Only on drug admin days – SASH or PRN to maintain IV access and patency PIV – NS 5 mL (Heparin 10 units/mL 3-5 mL if multiple days) PORT/PICC – NS 10 mL & Heparin 100 units/mL 3-5 mL, and/or 10 mL sterile saline to access port a cath	Quantity: Refills:	
Epinephrine **nursing requires**	□ IM □ sc	Adult 1:1000, 0.3 mL (>30 kg/>66 lbs) Peds 1:2000, 0.3 mL (15-30 kg/33-66 lbs) Infant 0.1 mL/0.1 mL, 0.1 mL (7.5-15 kg/16.5-33 lbs) PRN severe allergic reaction – Call 911 May repeat in 5-15 minutes as needed	Quantity: Refills:	
Premed Antihistamine: Diphenhydramine Other:	Other:	Other:	Dose will be rounded to the nearest vial size	
Elush Orders	Peripheral Access Central Venus Access	0.9% Sodium Chloride flush with mL IV before and after medication and IVP for maintenance Heparin units per mL flush with units as final flush and as directed	Send quantity sufficient for medication days' supply	
Additional Medication:				
Patient is interested in patient support r	programs	STAMP SIGNATURE NOT ALLOWED Ancillary supplies and kits prov	ided as needed for administration	

6 PRESCRIBER SIGNATURE REQUIRED (STAMP SIGNATURE NOT ALLOWED)

"Dispense As Written" / Brand Medically Necessary / DAW / May Not Substitute Prescriber's Signature:	Do Not Substitute / No Substitution /Date:	May Substitute / Product Selection Permitted / Substitution Permissible Prescriber's Signature:	Date:
CA, MA, NC & PR: Interchange is mandated unless Presc	riber writes the words " No Substitution "	ATTN: New York and Iowa providers, please submit electronic prescription	

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments. Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty and/or one of its affiliates.

©2022 CVS Specialty and one of its affiliates. 75-55131A 05/18/22